Professional Media briefs: May 2014

Share this article:
Ivan Oransky
Ivan Oransky

BMJ and the Lupus Foundation of America have published the first articles for Lupus Science & Medicine, which the partners said is the first lupus-specific open-access journal. Lupus Foundation CEO and President Sandra Raymond said in a statement that the foundation's publishing efforts have been scattered across non-lupus publications and that this journal “provides a much needed, centralized home for… lupus research findings.”

MedPage Today's Ivan Oransky's Retraction Watch has launched a subscriber service. Oransky (pictured) and partner Adam Marcus announced the service in a March post, alerting readers that subscriptions to the four-year-old blog would go toward such things as paying writers and creating a database. Funds will be handled by a third party, so as to protect the site's independence.

John Wiley & Sons has updated its 2006 Best Practice Guidelines on Publishing Ethics: A Publisher's Perspective. The goal remains to be a touchstone for advice on what the company calls “the major ethical principles of academic publishing.” The new edition includes guidance about whistle-blowers, clinical trial registration and other subjects.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?